US 12,473,553 B2
RNA nanostructures and methods of making and using RNA nanostructures
Hao Yan, Chandler, AZ (US); Yung Chang, Tempe, AZ (US); Xiaowei Liu, Tempe, AZ (US); Fei Zhang, Chandler, AZ (US); and Xiaodong Qi, Tempe, AZ (US)
Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
Filed by ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
Filed on Nov. 5, 2021, as Appl. No. 17/520,113.
Application 17/520,113 is a continuation of application No. 16/642,792, granted, now 11,254,941, previously published as PCT/US2018/048973, filed on Aug. 30, 2018.
Claims priority of provisional application 62/637,807, filed on Mar. 2, 2018.
Claims priority of provisional application 62/630,020, filed on Feb. 13, 2018.
Claims priority of provisional application 62/625,965, filed on Feb. 2, 2018.
Claims priority of provisional application 62/596,697, filed on Dec. 8, 2017.
Claims priority of provisional application 62/594,473, filed on Dec. 4, 2017.
Claims priority of provisional application 62/594,471, filed on Dec. 4, 2017.
Claims priority of provisional application 62/552,183, filed on Aug. 30, 2017.
Prior Publication US 2022/0056450 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/117 (2010.01); B82Y 5/00 (2011.01)
CPC C12N 15/117 (2013.01) [B82Y 5/00 (2013.01); C12N 2310/51 (2013.01)] 18 Claims
 
1. A method of inducing an immune response in a subject, comprising administering to the subject a therapeutically effective amount of an RNA nanostructure,
wherein the RNA nanostructure comprises at least two structural repeating units of 33 nucleotides in length, and wherein each structural repeating unit comprises, in order: a first region of a double helix wherein the first region is 9 or fewer nucleotides in length, a first paranemic cohesion crossover of 7 or greater nucleotides in length, a second region of a double helix wherein the second region is 10 or fewer nucleotides in length, and a second paranemic cohesion crossover of 7 or greater nucleotides in length, or
wherein the RNA nanostructure has a three-dimensional structure and comprises:
(HD1-LD1-HD2-LD2)n
wherein n is selected from 2 to 6000;
wherein HD1 and HD2 are each an RNA helical domain;
wherein LD1 and LD2 each comprise at least one paranemic cohesion crossover,
wherein the RNA nanostructure further comprises at least one agent which is operably linked to said RNA nanostructure, wherein the agent is selected from a diagnostic agent or a therapeutic agent.